← Back to headlines
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis
13 Mar, 07:22 — 13 Mar, 07:22
Sources
Showing 1 of 1 sources
Related Stories
Global health experts want risk-based regulation of nicotine products
just now
Bogus dentist in Albay town nabbed in police entrapment
just now
Smanjuje se broj slučajeva gripa i respiratornih infekcija
8m ago
Delfi diena. Kaip apsisaugoti nuo erkių ir kaip šiandien atrodo Lietuvos mados industrija?
8m ago